Ovid Therapeutics Inc. — Form 10-Q Summary
Business Context and Reporting Period
Ovid Therapeutics is a development-stage biopharmaceutical company focused on medicines for rare neurological disorders. This unaudited quarterly report covers the three months ended March 31, 2021, with comparison to the three months ended March 31, 2020. The company has no approved drugs and has never generated revenue from commercial drug sales.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Total revenue | $208.4 million | $0 | +$208.4 million |
| Research and development expense | $16.2 million | $14.6 million | +$1.6 million |
| General and administrative expense | $15.6 million | $5.7 million | +$9.9 million |
| Total operating expenses | $31.8 million | $20.3 million | +$11.5 million |
| Income from operations | $176.6 million | $(20.3) million | +$196.9 million |
| Net income (loss) | $176.0 million | $(20.0) million | +$196.0 million |
| Diluted EPS | $2.53 | $(0.37) | +$2.90 |
| Net cash provided by operating activities | $160.9 million | $(18.4) million | +$179.3 million |
| Cash and cash equivalents at period end | $233.1 million | $27.3 million | +$205.7 million |
Revenue and profitability were substantially affected by non-recurring licensing transactions. Based on reported figures, the operating margin was approximately 84.7% and the net margin approximately 84.5%; these margins are not representative of the company’s underlying development-stage operations.
- Revenue: $12.4 million from the Angelini license arrangement and $196.0 million of related-party license revenue from the Takeda License and Termination Agreement.
- Liquidity: $233.1 million of cash and cash equivalents at March 31, 2021, including approximately $231.2 million in money market funds. Working capital was $220.3 million.
- Debt: The company reported no long-term debt or capital leases and no material contractual obligations or commitments as of March 31, 2021.
- Equity: Total stockholders’ equity was $221.1 million, compared with $43.6 million at December 31, 2020. The company had 67.8 million common shares outstanding at March 31, 2021 and 67.8 million shares outstanding as of May 6, 2021.
- Cash runway: Management believes existing cash will fund current operating plans through at least 12 months from the filing date.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $208.4 million, primarily because of the $196.0 million Takeda upfront payment and $12.4 million recognized under the Angelini arrangement.
- Net income of $176.0 million replaced the prior-year net loss of $20.0 million. The improvement was primarily transaction-driven rather than recurring.
- Research and development expense increased 11% to $16.2 million, reflecting development activity and collaboration-related costs, partially offset by $2.6 million of Takeda cost reimbursements recorded as a credit.
- General and administrative expense increased 175% to $15.6 million, principally due to $8.2 million of one-time legal and professional fees related to the Takeda transaction.
- Operating cash flow improved to $160.9 million, largely reflecting the Takeda upfront payment and related accounting adjustments.
- Cash increased by $161.0 million from December 31, 2020, primarily because of the Takeda payment.
- In March 2021, 2,000 shares of Series A convertible preferred stock were converted into 2.0 million common shares.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- In March 2021, Takeda obtained global rights to soticlestat/OV935 and assumed responsibility for its development and commercialization. Ovid received $196.0 million upfront and may receive up to $660.0 million in development, regulatory and sales milestones, plus tiered royalties ranging from the low double-digits up to 20% if approved.
- In March 2021, Angelini terminated its license agreement effective March 31, 2021. Ovid recognized $12.4 million of related revenue but will not receive future milestone payments under the agreement.
- In April 2021, after the reporting period, Ovid announced that it would discontinue OV101 development in Angelman syndrome and would not initiate further OV101 clinical studies in Fragile X syndrome. Resources are being redirected toward the early-stage pipeline, including OV882.
- Management expects substantial operating losses and significant expenses for at least the next several years despite Q1 2021 net income. The company expects research and development expenses to increase as programs advance.
- The company has never generated commercial drug-sale revenue and remains dependent on regulatory approval, clinical success, collaborators, licensing transactions and future financing.
- Potential contingent payments under licensing arrangements, including up to $189.0 million under the Lundbeck agreement and up to $5.3 million under the Northwestern agreement, were not considered probable as of March 31, 2021. Total potential milestone obligations disclosed in contractual commitments were up to $194.3 million, excluding royalties.
- Key risks include clinical-trial failure or delay, regulatory non-approval, reliance on third-party manufacturers and contract research organizations, intellectual-property challenges, dependence on Takeda for future milestone and royalty payments, COVID-19 disruptions, and the need for additional capital.
- The company had a $250.0 million shelf registration capacity available as of March 31, 2021, including a $75.0 million at-the-market program; no shares had been sold under the 2020 ATM agreement by that date.
- Management concluded that disclosure controls and procedures were effective as of March 31, 2021, and reported no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm that Q1 revenue and earnings are dominated by the one-time Takeda transaction and should not be treated as recurring operating performance.
- Monitor Takeda’s development progress for soticlestat/OV935, including the likelihood and timing of the disclosed milestone payments and future royalties.
- Assess the effect of discontinuing OV101 and the company’s ability to advance OV882 and other early-stage programs.
- Review cash burn after the Takeda proceeds and update the expected runway as development spending changes.
- Evaluate the company’s continuing need for additional financing despite $233.1 million of cash at quarter-end.
- Track potential Lundbeck and Northwestern milestone obligations, royalty exposure and any changes in their probability or timing.
- Consider dilution from 11.0 million outstanding stock options and 1.25 million common shares issuable upon conversion of Series A preferred stock.